Disappointment especially in H2/2017 hit the shares. MDxHealth's potential in prostate cancer diagnosis remains intact; creating a significant opportunity for investors. Test volumes of marketed diagnostics are growing and should accelerate with a fully installed US salesforce and expanding European distribution network. Broadening US reimbursement and product coding should see ConfirmMDx volumes translate into revenues as payment collection accelerates. Data expected during 2018 supporting the ....
27 Feb 2018
Growth in prospect a compelling opportunity
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Growth in prospect a compelling opportunity
MDxHealth S.A. (0O8G:LON) | 0 0 0.3% | Mkt Cap: 168.5m
- Published:
27 Feb 2018 -
Author:
Chris Redhead -
Pages:
14
Disappointment especially in H2/2017 hit the shares. MDxHealth's potential in prostate cancer diagnosis remains intact; creating a significant opportunity for investors. Test volumes of marketed diagnostics are growing and should accelerate with a fully installed US salesforce and expanding European distribution network. Broadening US reimbursement and product coding should see ConfirmMDx volumes translate into revenues as payment collection accelerates. Data expected during 2018 supporting the ....